UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
Go back to UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 219.05 +3.04 (1.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $216.01 | 52 Week High | $333.65 | |||
| Open | $217.68 | 52 Week Low | $223.02 | |||
| Day High | $219.41 | P/E | 28.05 | |||
| Day Low | $215.33 | EPS | $7.81 | |||
| Volume | 836,707 | |||||
